前FDA审评员Paz Vellanki:首次人体试验可能成为关键性研究时,申办方应更早规划CMC
Sponsors Should Plan CMC Earlier When a First-in-Human Study Could Be Pivotal, Says Former FDA Reviewer Paz Vellanki
Precision for Medicine临床开发副总裁、前FDA审评员Paz Vellanki指出,若首次人体试验可能支持上市申请,申办方需更早考虑CMC要求。
News|Videos|November 12, 2026
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
When FDA launched its Rare Disease Framework Initiative on October 14, 2026, it opened a broader question for sponsors of small-population programs. If the first study in humans could support a marketing application, how early does manufacturing planning have to start?
Earlier than many sponsors expect, according to Paz Vellanki, MD, PhD, vice president of clinical development at Precision for Medicine and a former supervisory associate director in FDA's Division of Oncology 2. In the first part of a two-part video interview with BioPharm International®, Vellanki discussed phase-appropriate chemistry, manufacturing, and controls (CMC) requirements and the program elements she said sponsors tend to raise too late.
"FDA is not saying that standards are going to be lower in terms of administering a safe product to patients, but they are saying or are signaling that evidence generation might be different for these rare disease populations." – Dr. Paz Vellanki
"So if sponsors are now thinking about a first in human trial, potentially supporting a marketing application, we need to be thinking earlier about the requirements that might be needed from a CMC standpoint," Vellanki said.
She described the difference between the two stages of review. "At the IND stage, we think about can you control the quality or purity of a product, and then at the BLA stage or the NDA stage, we're thinking about additional things such as can we inspect the manufacturing processes? Can we ensure that those are met at very high standards?" she said.
Vellanki said that framing was already familiar inside the agency. "I came from the FDA. There, we thought a lot about seamless drug design, so we didn't always call out phase one, phase two, phase three," she said.
Beyond CMC, she pointed to two other areas that sponsors often leave until the end of phase 2: biomarker development for an assay that might become a companion diagnostic, and dosage selection. "I think these are all things that need to be moved earlier and considered earlier," she said.
How can manufacturing and assay readiness delay a trial?
Vellanki said a protocol that FDA clears can still stall before the first patient is dosed. "We have certainly seen scenarios where [an] IND has been submitted to the FDA. FDA has said that the protocol is safe to proceed, and then there's some delay in initiating the trial, and that might be related to manufacturing delays, or it could also be related to delays with assay development," she said.
The assay risk is greatest, she said, when enrollment depends on identifying a biomarker-selected population.
FDA has committed to risk-based CMC review for rare diseases but has not defined risk. Asked what a reasonable definition would look like, Vellanki began, "I want to preface things by saying that I am not an expert in CMC, but I do want to answer your question." She said CMC requirements were a major topic at FDA's October 28 public meeting on the initiative, but the agency did not define risk there.
"I think right now FDA is really calling for multi-stakeholder and external expertise, and they want input on how to define risk," she said. "Safety is going to be paramount no matter what."
Vellanki applied the same logic to FDA's "fit for purpose" language. "So fit for purpose, I think, acknowledges again that in the rare disease space, you may not have these large randomized trials that you might see in more common disease spaces," she said. "I think it's about trying to understand what evidence is required to be generated, and what risk we're comfortable with understanding what's possible."
FDA is accepting comments on the initiative through December 11, 2026, under docket FDA-2026-N-12214.
About the Speaker
Paz Vellanki, MD, PhD, vice president of clinical development, Precision for Medicine
Paz Vellanki joined Precision for Medicine after nearly seven years at FDA, where she worked in the Division of Oncology 2 from August 2019 to May 2026. She served as a medical officer, then as a clinical team lead, and from May 2024 as supervisory associate director. The division oversees drug development for thoracic and head and neck malignancies, neurologic tumors, pediatric solid tumors, and rare diseases.
Related to this article
November 12th, 2026
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
November 12th, 2026
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
November 12th, 2026
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
November 11th, 2026
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
November 11th, 2026
ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.
November 11th, 2026
Full phase 3 OASIZ-301 results show both dosing regimens of Amgen’s CD40L antagonist fusion protein dazodalibep reduced systemic disease activity in Sjögren’s disease at Week 48. The every-four-weeks dose also improved patient-reported dryness.
November 10th, 2026
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
November 10th, 2026
Larimar Therapeutics has completed its rolling BLA for nomlabofusp, a frataxin replacement fusion protein, seeking accelerated approval based on skin frataxin as a novel surrogate endpoint. The company expects a potential US approval in mid-2027.
来源:BioPharm International · biopharminternational.com





